NCT01729091
|
Phase Ib/II |
Dexamethasone
Elotuzumab
Filgrastim
Melphalan
Lenalidomide
|
Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma |
Recruiting |
NCT02685826
|
Phase I |
Dexamethasone
lenalidomide + MEDI4736
|
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma |
Active, not recruiting |
NCT03418038
|
Phase II |
Dexamethasone
Carboplatin + Etoposide + Ifosfamide
Carboplatin + Etoposide + Ifosfamide + Rituximab
Cisplatin + Cytarabine + Dexamethasone
Cisplatin + Dexamethasone + Gemcitabine
Rituximab
Cytarabine + Dexamethasone + Oxaliplatin
Gemcitabine + Oxaliplatin
Cisplatin + Cytarabine + Dexamethasone + Rituximab
|
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma |
Recruiting |
NCT01363817
|
Phase I |
Dexamethasone
BMS-906024
|
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma |
Completed |
NCT02506959
|
Phase II |
Dexamethasone
Busulfan + Melphalan
Pyridoxine
Panobinostat
Palifermin
Gemcitabine
|
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma |
Recruiting |
NCT01483690
|
Phase Ib/II |
Pegaspargase
Methotrexate
Dexamethasone
Vincristine
Decitabine
Mitoxantrone
|
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL |
Terminated |
NCT03259503
|
Phase Ib/II |
Busulfan
Olaparib
Vorinostat
Palifermin
Gemcitabine
Melphalan
Dexamethasone
Pyridoxine
Rituximab
|
Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas |
Not yet recruiting |
NCT03117751
|
Phase II |
Cyclophosphamide
Vincristine
Idarubicin
Blinatumomab
Doxorubicin
Clofarabine
Vorinostat
Ruxolitinib
Prednisone
Bortezomib
Etoposide
Dasatinib
Daunorubicin
Dexamethasone
Rituximab
Methotrexate
Cytarabine
Mercaptopurine
Pegaspargase
|
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma |
Recruiting |
NCT02030483
|
Phase I |
Palbociclib
Dexamethasone
Lenalidomide
|
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma |
Terminated |
NCT02419755
|
Phase II |
Cytarabine
Mercaptopurine
Methotrexate
Pegaspargase
Vorinostat
Doxorubicin
Bortezomib
Dexamethasone
Mitoxantrone
Prednisone
|
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies |
Terminated |
NCT01428492
|
Phase I |
Afuresertib
Bortezomib
Dexamethasone
|
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma |
Completed |
NCT01863550
|
Phase III |
Dexamethasone
Lenalidomide
Carfilzomib
Bortezomib
|
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma |
Recruiting |
NCT03147612
|
Phase II |
Mesna
Vincristine
Dexamethasone
Rituximab
Filgrastim
Ponatinib
Cyclophosphamide
Methotrexate
Cytarabine
|
Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) |
Recruiting |
NCT02352558
|
Phase I |
Imatinib
Napabucasin
Bortezomib
Ibrutinib
Dexamethasone
|
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies |
Active, not recruiting |
NCT02464657
|
Phase Ib/II |
Dexamethasone
Cytarabine + Idarubicin + Nivolumab
|
Nivolumab in Acute Myeloid Leukemia (AML) |
Recruiting |
NCT00549848
|
Phase III |
Vincristine + Pegaspargase + Daunorubicin
Cytarabine
Mercaptopurine
Thioguanine
Clofarabine + Etoposide + Cyclophosphamide
Methotrexate
Dasatinib
Doxorubicin
Dexamethasone
|
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia |
Active, not recruiting |
NCT01422746
|
|
Metformin
Dexamethasone
|
Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess |
Recruiting |
NCT02279394
|
Phase II |
Dexamethasone
Elotuzumab + lenalidomide
|
Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma |
Active, not recruiting |
NCT01846611
|
Phase III |
Doxil
Dexamethasone
|
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Completed |
NCT02400242
|
Phase I |
Citarinostat
Dexamethasone
Pomalidomide
|
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma |
Active, not recruiting |
NCT02579863
|
Phase III |
Pembrolizumab
Dexamethasone
Lenalidomide
|
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) |
Active, not recruiting |
NCT02518113
|
Phase Ib/II |
Dexamethasone
LY3039478
|
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL |
Completed |
NCT02490878
|
Phase II |
Dexamethasone
Prednisone
Bevacizumab
|
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases |
Active, not recruiting |
NCT02265510
|
Phase I |
Gemcitabine
Carfilzomib
Dexamethasone
Lenalidomide
nab-paclitaxel
Azacitidine
INCB052793
Bortezomib
|
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies |
Active, not recruiting |
NCT03411031
|
Phase II |
Elotuzumab + lenalidomide
Dexamethasone
|
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide |
Recruiting |
NCT01962792
|
Phase Ib/II |
Carfilzomib + Ibrutinib
Dexamethasone
|
Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma |
Active, not recruiting |
NCT02616640
|
Phase I |
Pomalidomide
Dexamethasone
Durvalumab
|
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
Active, not recruiting |
NCT02605356
|
Phase Ib/II |
radium Ra 223 dichloride
Bortezomib
Dexamethasone
|
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma |
Withdrawn |
NCT02906332
|
Phase II |
Pembrolizumab
Dexamethasone
|
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) |
Active, not recruiting |
NCT01319981
|
Phase II |
Pegfilgrastim
Imatinib
Filgrastim
Rituximab
Doxorubicin
Dexamethasone
Vincristine
Cyclophosphamide
|
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia |
Active, not recruiting |
NCT02576977
|
Phase III |
Pomalidomide
Pembrolizumab
Dexamethasone
|
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) |
Active, not recruiting |
NCT02520115
|
Phase I |
Dexamethasone
Valproic acid
|
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer |
Recruiting |
NCT03007147
|
Phase III |
Pegaspargase
Methotrexate
Leucovorin
Cytarabine
Mercaptopurine
Thioguanine
Vincristine
Cyclophosphamide
Imatinib
Ifosfamide
dexrazoxane
Daunorubicin
Dexamethasone
Methylprednisolone
Etoposide
Prednisolone
Doxorubicin
|
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
Recruiting |
NCT02420860
|
Phase II |
Famotidine
Elotuzumab + lenalidomide
Diphenhydramine
Dexamethasone
|
Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT) |
Recruiting |
NCT01256398
|
Phase II |
Dexamethasone
Dasatinib
Tacrolimus
Cyclophosphamide + Fludarabine
Filgrastim
Vincristine + Methotrexate + Mercaptopurine
Melphalan
Cytarabine + Daunorubicin + Etoposide
Pegfilgrastim
Alemtuzumab
Leucovorin
|
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
Active, not recruiting |
NCT02491411
|
Phase I |
Enzalutamide
Dexamethasone
|
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel |
Terminated |
NCT02471911
|
Phase I |
Dexamethasone
Carboplatin + Etoposide + Ifosfamide + Rituximab
Selinexor
|
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma |
Recruiting |
NCT02036502
|
Phase I |
Dexamethasone
lenalidomide + Pembrolizumab
|
A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) |
Active, not recruiting |
NCT03571321
|
Phase I |
Pegaspargase
Methotrexate
Cytarabine
Mercaptopurine
Thioguanine
Ruxolitinib
Cyclophosphamide
Dexamethasone
Vincristine
Rituximab
Doxorubicin
|
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia |
Not yet recruiting |
NCT01459211
|
Phase II |
Dexamethasone
Lenalidomide
|
Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) |
Completed |
NCT01983969
|
Phase Ib/II |
Rituximab
Dexamethasone
Busulfan + Melphalan
Azacitidine + Gemcitabine + vorinostat
|
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma |
Completed |
NCT02553460
|
Phase II |
Cyclophosphamide
Mitoxantrone
Dexamethasone
Bortezomib
Etoposide
Vincristine
Pegaspargase
Vorinostat
Cytarabine
Methotrexate
Leucovorin
|
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I |
Recruiting |
NCT02427620
|
Phase II |
Cyclophosphamide + Doxorubicin + Vincristine
Filgrastim
Dexamethasone
Cytarabine + Methotrexate
Leucovorin
|
A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma |
Recruiting |
NCT02419495
|
Phase I |
Cyclophosphamide
Pemetrexed
Eribulin
Selinexor
Carboplatin
Paclitaxel
Topotecan
Dexamethasone
Doxorubicin
|
Selinexor in Combination With Standard Chemotherapy |
Recruiting |
NCT02532192
|
Phase I |
Rituximab
Cisplatin
Dexamethasone
Cytarabine
Fluconazole
Belinostat
|
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma |
Withdrawn |
NCT03150693
|
Phase III |
Rituximab
Doxorubicin
Mercaptopurine
Methotrexate
Cyclophosphamide + Cytarabine
Thioguanine
Allopurinol
Daunorubicin
Dexamethasone
Vincristine
inotuzumab ozogamicin
|
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia |
Recruiting |
NCT03020030
|
Phase III |
Nelarabine
dexrazoxane
Asparaginase
Vincristine
Cyclophosphamide
Cytarabine
Mercaptopurine
Pegaspargase
Methotrexate
Etoposide
Doxorubicin
Dexamethasone
Prednisone
Dasatinib
Leucovorin
|
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents |
Recruiting |
NCT03004287
|
Phase II |
Melphalan
Carfilzomib
Cisplatin
Cyclophosphamide
Lenalidomide
Dexamethasone
Daratumumab
Bortezomib
Etoposide
Doxorubicin
Thalidomide
|
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy |
Recruiting |
NCT02112916
|
Phase III |
Cyclophosphamide
Vincristine
Ifosfamide
Pegaspargase
Methotrexate
Cytarabine
Mercaptopurine
Thioguanine
Leucovorin
Daunorubicin
Dexamethasone
Bortezomib
Etoposide
Doxorubicin
|
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma |
Suspended |
NCT02211014
|
Phase I |
Acalabrutinib
Dexamethasone
|
An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma |
Active, not recruiting |
NCT02589145
|
Phase Ib/II |
Lenalidomide
Pyridoxine
Dexamethasone
Busulfan + Melphalan
Enoxaparin
Rituximab
Gemcitabine
Vorinostat
Palifermin
|
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype |
Active, not recruiting |
NCT01455389
|
Phase Ib/II |
DOTAP:chol-Fus1
Erlotinib
Diphenhydramine
Dexamethasone
|
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer |
Active, not recruiting |